8-K: Tempest Therapeutics Explores Strategic Alternatives Amidst Capital Market Challenges

Tempest Therapeutics announces it is exploring strategic alternatives, including potential mergers or acquisitions, due to unfavorable capital market conditions despite positive clinical data.

Summary

• Tempest Therapeutics is exploring strategic alternatives to maximize stockholder value.
• The company has retained MTS Health Partners, L.P. to assist with the evaluation process.
• Strategic alternatives under consideration include mergers, acquisitions, partnerships, joint ventures, and licensing arrangements.
• This decision comes despite positive Phase 2 data for amezalpat in hepatocellular carcinoma (HCC) and the potential of TPST-1495 in familial adenomatous polyposis (FAP).
• The company repaid $3.5 million under its Loan and Security Agreement with Oxford Finance LLC, including a $0.6 million exit fee, terminating the agreement.
• Amezalpat has received Orphan Drug and Fast Track designations from the FDA for HCC treatment.
• The FDA has granted a Study May Proceed letter for a Phase 3 trial of amezalpat in combination with atezolizumab and bevacizumab for first-line HCC.
• TPST-1495 has received Orphan Drug designation from the FDA for FAP treatment.
• The FDA has granted a Study May Proceed letter for a Phase 2 trial of TPST-1495 for the treatment of FAP, expected to begin in 2025.
• The company does not intend to disclose further developments unless it is determined that further disclosure is appropriate or necessary.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has promising clinical assets and has achieved regulatory milestones, it is exploring strategic alternatives due to funding challenges, indicating uncertainty about its future.

Positives

• Amezalpat has shown positive Phase 2 data and has blockbuster potential in first-line HCC.
• TPST-1495 has potential as it moves towards a Phase 2 trial in FAP.
• Amezalpat has received Orphan Drug and Fast Track designations from the FDA.
• TPST-1495 has received Orphan Drug designation from the FDA.
• The FDA has granted Study May Proceed letters for both amezalpat and TPST-1495 clinical trials.
• Amezalpat demonstrated a six-month improvement in median overall survival (OS) when combined with atezolizumab and bevacizumab in first-line HCC patients in a Phase 1b/2 study.

Negatives

• The company is exploring strategic alternatives due to unfavorable capital market conditions.
• There is no guarantee that the strategic evaluation process will result in a transaction.
• The company has not set a timetable for completion of the strategic evaluation process.

Risks

• Volatility and uncertainty in the capital markets for biotechnology companies could hinder strategic transactions.
• Suitable third parties may not be available to conduct contemplated strategic transactions.
• The company may not be able to pursue a strategic transaction, or any transaction, if pursued, may not be completed on attractive terms or at all.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company is exploring strategic alternatives to advance its clinical-stage programs and maximize stockholder value, but there is no guarantee that any transaction will result from this process.

Management Comments

• Stephen Brady, president and chief executive officer of Tempest, stated that the capital markets have been unavailable to support the next stage of advancement despite positive data.
• Stephen Brady believes that initiating a process to explore alternatives available to the company to maximize stockholder value, which include finding a strategic partner with the resources to develop what they believe are potentially life-saving therapies for patients in need.
• Stephen Brady believes that given the positive data and commercial potential with this pipeline, as well as the clearance from FDA on the lead programs pivotal study, this is a rare opportunity for a partner.

Industry Context

Many biotechnology companies face challenges in securing funding, especially in volatile capital markets, leading them to explore strategic alternatives such as mergers or acquisitions to continue development programs.

Comparison to Industry Standards

• The decision to explore strategic alternatives is a common response in the biotech industry when companies with promising clinical assets face funding challenges, similar to situations seen with companies like Sierra Oncology before its acquisition by GSK.
• The six-month improvement in median overall survival (OS) with amezalpat in HCC is a clinically meaningful result, comparable to survival benefits seen with other approved therapies in this indication, such as atezolizumab plus bevacizumab.
• The Orphan Drug and Fast Track designations for amezalpat are similar to those granted to other drugs targeting rare cancers, providing potential benefits such as market exclusivity and accelerated review.

Stakeholder Impact

• Shareholders may experience changes in the value of their investment depending on the outcome of the strategic evaluation process.
• Employees may be affected by potential mergers, acquisitions, or restructuring activities.
• Patients may benefit from the continued development of the company's clinical programs if a strategic partner is found.

Next Steps

• The company will continue to evaluate strategic alternatives with the assistance of MTS Health Partners, L.P.
• The Phase 2 study of TPST-1495 in patients with FAP is expected to begin in 2025.

Key Dates

Keywords

strategic alternatives, amezalpat, TPST-1495, Tempest Therapeutics, clinical trials, oncology, HCC, FAP, biotechnology, FDA